

Prof.Dr. GÜNEŞ ESENDAĞLI

Kişisel Bilgiler

İş Telefonu: [+90 312 305 4322](tel:+903123054322)

İş Telefonu: [+90 312 305 4413](tel:+903123054413)

Fax Telefonu: [+90 312 324 2009](tel:+903123242009)

E-posta: gunese@hacettepe.edu.tr

Web: <https://www.esendagilab.com>

Eğitim Bilgileri

Doktora, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Kanser Enstitüsü Temel Onkoloji Anabilim Dalı, Türkiye 2003 - 2007

Yüksek Lisans, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Kanser Enstitüsü Temel Onkoloji Anabilim Dalı, Türkiye 2001 - 2003

Lisans, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Biyolojik Bilimler Bölümü, Türkiye 1997 - 2001

Yabancı Diller

İngilizce, B2 Orta Üstü

Fransızca, B1 Orta

Yaptığı Tezler

Doktora, Kimyasal karsinogenezle oluşturulmuş meme tümör hücrelerinin CD40 ligand ile genetik modifikasyonu ve allojenik aşı preparatı olarak kullanılabilirliğinin değerlendirilmesi, Hacettepe Üniversitesi, Kanser Enstitüsü , Tümör Biyolojisi Ve İmmünolojisi (YI) (Tezli), 2007

Yüksek Lisans, CD40 ligand (CD154) genin ökaryotik ekspresyon vektörüne klonlanması, Hacettepe Üniversitesi, Kanser Enstitüsü , Temel İmmünoloji (YI) (Tezli), 2003

Araştırma Alanları

Tıp, Sağlık Bilimleri, Temel Tıp Bilimleri, Mikrobiyoloji ve Klinik Mikrobiyoloji, İmmünoloji, Tıbbi Biyoloji, Yaşam Bilimleri, Moleküler Biyoloji ve Genetik , Kanser Moleküler Biyolojisi, Temel Bilimler

Akademik İdari Deneyim

Hacettepe Üniversitesi, Kanser Enstitüsü , 2012 - Devam Ediyor

Üniversite Yönetim Kurulu Üyesi, Hacettepe Üniversitesi, 2017 - 2019

Verdiği Dersler

TİM 601 - Temel İmmünoloji I, Yüksek Lisans, 2017 - 2018

KBI 602-TEMEL İMMÜNOLOJİ VE TÜRÖR BİYOLOJİSİ II, Yüksek Lisans, 2016 - 2017, 2017 - 2018

KBI 601-TEMEL İMMÜNOLOJİ VE TÜRÖR BİYOLOJİSİ I, Yüksek Lisans, 2016 - 2017, 2017 - 2018

KBİ 701-TEMEL ONKOLOJİ LABORATUVAR TEKNİKLERİ, Doktora, 2016 - 2017, 2017 - 2018

TİM 602 - Temel İmmünoloji II, Yüksek Lisans, 2017 - 2018

KBİ 722 - TEMEL İMMÜNOLOJİ II, Doktora, 2016 - 2017, 2017 - 2018

KBİ 721-TEMEL İMMÜNOLOJİ I, Doktora, 2016 - 2017, 2017 - 2018

Yönetilen Tezler

ESENDAĞLI G., The effect of inducible costimulatory ligand (İCOS-LG) expressing myeloid leukemia cells on helper t lymphocyte activation and exhaustion, Yüksek Lisans, D.ÖZKAZANÇ(Öğrenci), 2015

ESENDAĞLI G., All-trans retinoik asit (ATRA) ve 1 α ,25-dihidroksivitamin D3 (vitamin D3) ile uyarılan akut miyeloid lösemi hücrelerinin T hücre yanıtları üzerine etkisi, Yüksek Lisans, D.YÖYEN(Öğrenci), 2014

GÜÇ D., ESENDAĞLI G., Fibroblast-breast cancer cells' interaction and Chemerin expression, Doktora, D.RAMA(Öğrenci), 2011

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier**
Seko I., TONBUL H., Tavukcuoglu E., Sahin A., AKBAŞ S., Yanik H., ÖZTÜRK S. C. , ESENDAĞLI G., Khan M., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.66, 2021 (SCI İndekslerine Giren Dergi)
- II. **Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral camptothecin delivery in early and late-stage colorectal tumor-bearing animal model**
Unal S., ÖZTÜRK S. C. , BİLGİÇ E., Yanik H., KORKUSUZ P., AKTAŞ Y., Benito J. M. , ESENDAĞLI G., BİLENSOY E.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, cilt.169, ss.168-177, 2021 (SCI İndekslerine Giren Dergi)
- III. **Functional responsiveness of memory T cells from COVID-19 patients**
Tavukcuoglu E., Horzum U., İNKAYA A. Ç. , ÜNAL S., ESENDAĞLI G.
CELLULAR IMMUNOLOGY, cilt.365, 2021 (SCI İndekslerine Giren Dergi)
- IV. **Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes**
KURŞUNEL M. A. , Taskiran E. Z. , Tavukcuoglu E., Yanik H., Demirag F., KARAOSMANOĞLU B., Ozbay F. G. , ÜNER A., Esendagli D., Kizilgoz D., et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 (SCI İndekslerine Giren Dergi)
- V. **Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells**
TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.63, 2021 (SCI İndekslerine Giren Dergi)
- VI. **Proerythroblast Cells of Diamond-Blackfan Anemia Patients With RPS19 and CECR1 Mutations Have Similar Transcriptomic Signature**
KARAOSMANOĞLU B., KURŞUNEL M. A. , ÇETİNKAYA F. D. , GÜMRÜK F., ESENDAĞLI G., ÜNAL Ş., Taskiran E. Z.
FRONTIERS IN PHYSIOLOGY, cilt.12, 2021 (SCI İndekslerine Giren Dergi)
- VII. **A robust optimization approach for the breast cancer targeted design of PetOx-b-PLA polymersomes**
ÖZ U. C. , Bolat Z. B. , Ozkose U. U. , Gulyuz S., KÜÇÜKTÜRKMEN B., PARLAK KHALİLY M., ÖZÇUBUKÇU S., Yilmaz O., TELCİ D., ESENDAĞLI G., et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, cilt.123, 2021 (SCI İndekslerine Giren Dergi)
- VIII. **Clinical Relevance of Polymorphonuclear Myeloid-Derived Suppressor Cells in Autoimmune-**

Blistering Disorders Pemphigus Vulgaris and Bullous Pemphigoid

Oktem A., Horzum U., Ertop P., KUNDAKCI N., Akay B. N. , Yalcin B., ESENDAĞLI G.

JOURNAL OF INVESTIGATIVE DERMATOLOGY, cilt.141, sa.3, ss.672-676, 2021 (SCI İndekslerine Giren Dergi)

- IX. **Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: Analyses in 3D tumor culture and tumor-bearing animals in vivo**
Varan G., VARAN C., ÖZTÜRK S. C. , Benito J. M. , ESENDAĞLI G., BİLENSOY E.
Nanomaterials, cilt.11, sa.2, ss.1-18, 2021 (SCI İndekslerine Giren Dergi)
- X. **An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy**
Acar N. P. , Tuncer A., Ozkazanc D., Ozbay F. G. , KARAOSMANOĞLU B., Goksen S., Sayat G., Taskiran E. Z. , ESENDAĞLI G., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, cilt.347, 2020 (SCI İndekslerine Giren Dergi)
- XI. **Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer**
Tavukcuoglu E., Horzum U., Yanik H., ÜNER A., Yoyen-Ermis D., NURAL S. K. , Aydin B., SÖKMENSÜER C., KARAKOÇ D., Yilmaz K. B. , et al.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2020 (SCI İndekslerine Giren Dergi)
- XII. **CD66b(+) monocytes represent a proinflammatory myeloid subpopulation in cancer**
Horzum U., Yoyen-Ermis D., Taskiran E. Z. , Yilmaz K. B. , HAMALOĞLU E., KARAKOÇ D., ESENDAĞLI G.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020 (SCI İndekslerine Giren Dergi)
- XIII. **Development and in vitro evaluation of temozolomide-loaded PLGA nanoparticles in a thermoreversible hydrogel system for local administration in glioblastoma multiforme**
Sayiner O., Arisoy S., ÇOMOĞLU T., Ozbay F. G. , ESENDAĞLI G.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.57, 2020 (SCI İndekslerine Giren Dergi)
- XIV. **Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer**
KARPUZ M., Silindir-Gunay M., Kursunel M. A. , ESENDAĞLI G., DOĞAN A., ÖZER A. Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.57, 2020 (SCI İndekslerine Giren Dergi)
- XV. **Aggregation of chitosan nanoparticles in cell culture: Reasons and resolutions**
Ozturk K., Arslan F. B. , Tavukcuoglu E., ESENDAĞLI G., ÇALIŞ S.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.578, 2020 (SCI İndekslerine Giren Dergi)
- XVI. **Development and in vitro evaluation of a new adjuvant system containing Salmonella Typhi porins and chitosan**
YÜKSEL S., PEKCAN M., PURALI N., ESENDAĞLI G., Tavukcuoglu E., Rivero-Arredondo V., Ontiveros-Padilla L., Lopez-Macias C., ŞENEL S.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.578, 2020 (SCI İndekslerine Giren Dergi)
- XVII. **PD-L2(+) wound zone macrophage-like cells display M1/M2-mixed activation and restrain the effector Th1 responses**
Tavukcuoglu E., Horzum U., Yilmaz K. B. , ESENDAĞLI G.
IMMUNOLOGY AND CELL BIOLOGY, cilt.98, sa.2, ss.152-164, 2020 (SCI İndekslerine Giren Dergi)
- XVIII. **Protocol to assess the suppression of T-cell proliferation by human MDSC**
Bruger A. M. , Vanhaver C., Bruderek K., Amodio G., Tavukcuoglu E., ESENDAĞLI G., Gregori S., Brandau S., van der Bruggen P.
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - CELLULAR METHODS, PT B, cilt.632, ss.155-192, 2020 (SCI İndekslerine Giren Dergi)
- XIX. **Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation**
Cassetta L., Bruderek K., Skrzeczynska-Moncznik J., Osiecka O., Hu X., Rundgren I. M. , Lin A., Santegoets K., Horzum U., Godinho-Santos A., et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, cilt.8, sa.2, 2020 (SCI İndekslerine Giren Dergi)
- XX. **A method for high-purity isolation of neutrophil granulocytes for functional cell migration assays**

Avci E., Akkaya-Ulum Y. Z. , Yoyen-Ermis D., ESENDAĞLI G., Balci-Peynircioglu B.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.44, sa.6, ss.810-821, 2019 (SCI İndekslerine Giren Dergi)

- XXI. **Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer**
Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.54, 2019 (SCI İndekslerine Giren Dergi)
- XXII. **Identification of circulating MOG-specific B cells in patients with MOG antibodies**
Winkmeier S., Schlueter M., Spadaro M., Thaler F. S. , Vural A., Gerhards R., Macrini C., Mader S. A. , Kurne A., İNAN B., et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, cilt.6, sa.6, 2019 (SCI İndekslerine Giren Dergi)
- XXIII. **Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS**
Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.
SCIENTIFIC REPORTS, cilt.9, 2019 (SCI İndekslerine Giren Dergi)
- XXIV. **Primary tumor resection for initially staged IV breast cancer An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival**
Erol T., İmamoğlu N., Aydin B., Taşkıran Z., Esendağlı G., Kösemehmetoğlu K., Baykal A.
MEDICINE, cilt.98, sa.33, 2019 (SCI İndekslerine Giren Dergi)
- XXV. **Dual actions of the antioxidant chlorophyllin, a glutathione transferase P1-1 inhibitor, in tumorigenesis and tumor progression**
ÖZCAN M., ESENDAĞLI G., Musdal Y., CANPINAR H., BACANLI M., Anlar H. G. , Esendagli-Yilmaz G., Beyramzadeh M., AKSOY Y.
JOURNAL OF CELLULAR BIOCHEMISTRY, cilt.120, sa.5, ss.7045-7055, 2019 (SCI İndekslerine Giren Dergi)
- XXVI. **How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions**
Bruger A. M. , Dorhoi A., ESENDAĞLI G., Barczyk-Kahlert K., van der Bruggen P., Lipoldova M., Perecko T., Santibanez J., Saraiva M., Van Ginderachter J. A. , et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY, cilt.68, sa.4, ss.631-644, 2019 (SCI İndekslerine Giren Dergi)
- XXVII. **Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer**
TİMUR S. S. , Yoyen-Ermis D., Esendagli G., Yonat S., Horzum U., ESENDAĞLI G., GÜRİSOY R. N.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, cilt.136, ss.138-146, 2019 (SCI İndekslerine Giren Dergi)
- XXVIII. **A Novel Missense LIG4 Mutation in a Patient With a Phenotype Mimicking Behcet's Disease**
Taskiran E., Sonmez H., Kosukcu C., Tavukcuoglu E., Yazici G., Esendagli G., Batu E., Kiper P., Bilginer Y., Alikasifoglu M., et al.
JOURNAL OF CLINICAL IMMUNOLOGY, cilt.39, sa.1, ss.99-105, 2019 (SCI İndekslerine Giren Dergi)
- XXIX. **The fibrogenic activation kinetics of stromal stem cells in three different skeletal muscle degeneration models**
Ozdemir C., Akcay D., Ermis D. Y. , ESENDAĞLI G., Kocaefe C.
FEBS OPEN BIO, cilt.8, ss.93, 2018 (SCI İndekslerine Giren Dergi)
- XXX. **Dual Effect of Glucocorticoid-Induced Tumor Necrosis Factor-Related Receptor Ligand Carrying Mesenchymal Stromal Cells on Small Cell Lung Cancer: A Preliminary in vitro Study**
KÖPRÜ C. Z. , Cagnan I., AKAR İ., ESENDAĞLI G., KORKUSUZ P., Gunel-Ozcan A.
CYTOTHERAPY, cilt.20, sa.7, ss.930-940, 2018 (SCI İndekslerine Giren Dergi)
- XXXI. **Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody**
Yoyen-Ermis D., Ozturk-Atar K., KURŞUNEL M. A. , Aydin C., Ozkazanc D., Gurbuz M. U. , ÜNER A., TÜLÜ M., ÇALIŞ S., ESENDAĞLI G.
MOLECULAR PHARMACEUTICS, cilt.15, sa.4, ss.1526-1533, 2018 (SCI İndekslerine Giren Dergi)
- XXXII. **Impact of repeated abdominal surgery on wound healing and myeloid cell dynamics**

- ESENDAĞLI G., Yoyen-Ermis D., Guseinov E., Aras C., Aydin C., ÜNER A., HAMALOĞLU E., KARAKOÇ D.
JOURNAL OF SURGICAL RESEARCH, cilt.223, ss.188-197, 2018 (SCI İndekslerine Giren Dergi)
- XXXIII. **Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer**
ERDOĞAR N., ESENDAĞLI G., Nielsen T. T. , Esendagli-Yilmaz G., Yoyen-Ermis D., Erdogdu B., SARGON M. F. , EROĞLU H., BİLENSOY E.
JOURNAL OF DRUG TARGETING, cilt.26, sa.1, ss.66-74, 2018 (SCI İndekslerine Giren Dergi)
- XXXIV. **Development of novel self-assembled polymeric micelles from partially hydrolysed poly(2-ethyl-2-oxazoline)-co-PEI-b-PCL block copolymer as non-viral vectors for plasmid DNA in vitro transfection**
Kara A., Ozturk N., ESENDAĞLI G., Ozkose U. U. , Gulyuz S., Yilmaz O., Telci D., Bozkir A., VURAL İ.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, cilt.46, 2018 (SCI İndekslerine Giren Dergi)
- XXXV. **Effect of Usnic Acid/Paclitaxel Co-Administration on Mouse (4T1) Breast Cancer Cell Lines**
DİNÇSOY A. B. , Ermis D. Y. , CANSARAN DUMAN D., TUNCER M., KARABULUT İ., ESENDAĞLI G.
ACTA PHYSIOLOGICA, cilt.221, ss.40-41, 2017 (SCI İndekslerine Giren Dergi)
- XXXVI. **A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy**
KURŞUNEL M. A. , ESENDAĞLI G.
EBIOMEDICINE, cilt.23, ss.6-7, 2017 (SCI İndekslerine Giren Dergi)
- XXXVII. **Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers**
Ozturk K., ESENDAĞLI G., Gurbuz M. U. , TÜLÜ M., ÇALIŞ S.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.517, ss.157-167, 2017 (SCI İndekslerine Giren Dergi)
- XXXVIII. **Th1 cells in cancer-associated inflammation**
Dinc Akbulut G., Ozkazanc D., ESENDAĞLI G.
TURKISH JOURNAL OF BIOLOGY, cilt.41, sa.1, ss.20-30, 2017 (SCI İndekslerine Giren Dergi)
- XXXIX. **Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells**
Sahin A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF MICROENCAPSULATION, cilt.34, sa.7, ss.659-666, 2017 (SCI İndekslerine Giren Dergi)
- XL. **Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis**
Sevmis M., Yoyen-Ermis D., Aydin C., BİLGİÇ E., KORKUSUZ P., ÜNER A., HAMALOĞLU E., ESENDAĞLI G., KARAKOÇ D.
IMMUNOLOGICAL INVESTIGATIONS, cilt.46, sa.7, ss.663-676, 2017 (SCI İndekslerine Giren Dergi)
- XLI. **A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery**
ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., HORZUM U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, cilt.45, sa.8, ss.1657-1664, 2017 (SCI İndekslerine Giren Dergi)
- XLII. **Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells**
Özkazanç D., Yöyen-Ermiş D., Tavukçuoğlu E., BÜYÜKAŞIK Y., ESENDAĞLI G.
IMMUNOLOGY, cilt.149, sa.4, ss.460-471, 2016 (SCI İndekslerine Giren Dergi)
- XLIII. **The untold story of IFN-gamma in cancer biology**
KURŞUNEL M. A. , ESENDAĞLI G.
CYTOKINE & GROWTH FACTOR REVIEWS, cilt.31, ss.73-81, 2016 (SCI İndekslerine Giren Dergi)
- XLIV. **Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles**
ERDOĞAR N., ESENDAĞLI G., Nielsen T. T. , ŞEN M., ÖNER L., BİLENSOY E.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.509, ss.375-390, 2016 (SCI İndekslerine Giren Dergi)
- XLV. **Cytotoxicity and biodistribution studies on PEGylated EDA and PEG cored PAMAM dendrimers**

Gurbuz M. U. , Ozturk K, Erturk A. S. , YOYEN-ERMIS D., ESENDAĞLI G., ÇALIŞ S., TÜLÜ M.
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, cilt.27, sa.16, ss.1645-1658, 2016 (SCI İndekslerine Giren Dergi)

- XLVI. **CXCL7-induced macrophage infiltration in lung tumor is independent of CXCR2 expression: CXCL7-induced macrophage chemotaxis in LLC tumors.**
Unver N., ESENDAĞLI G., YILMAZ G., GUC D.
Cytokine, cilt.75, ss.330-7, 2015 (SCI Expanded İndekslerine Giren Dergi)
- XLVII. **Immune system in cancer and hydatid disease: cross-reactivity vs. immune modulation**
ESENDAĞLI G., ABBASOĞLU O.
PARASITE IMMUNOLOGY, cilt.37, sa.8, ss.427-428, 2015 (SCI İndekslerine Giren Dergi)
- XLVIII. **Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma**
DOLEN Y., GÜNEYDİN G., ESENDAĞLI G., GUC D.
CELLULAR IMMUNOLOGY, cilt.295, sa.1, ss.29-35, 2015 (SCI İndekslerine Giren Dergi)
- XLIX. **Co-existence of Echinococcus granulosus infection and cancer metastasis in the liver correlates with reduced Th1 immune responses**
Turhan N., ESENDAĞLI G., Ozkayar O., Tunali G., SÖKMENSÜER C., ABBASOĞLU O.
PARASITE IMMUNOLOGY, cilt.37, sa.1, ss.16-22, 2015 (SCI İndekslerine Giren Dergi)
- L. **CRAM-A indicates IFN-gamma-associated inflammatory response in breast cancer**
SARMADI P., Tunali G., Esendagli-Yilmaz G., YILMAZ K. B. , ESENDAĞLI G.
MOLECULAR IMMUNOLOGY, cilt.68, sa.2, ss.692-698, 2015 (SCI İndekslerine Giren Dergi)
- LI. **Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes' stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide**
KILIÇ A., ESENDAĞLI G., SAYAT G., TALİM B., KARABUDAK R., KURNE A.
AUTOIMMUNITY, cilt.48, sa.6, ss.423-428, 2015 (SCI İndekslerine Giren Dergi)
- LII. **T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands**
Karasar P., ESENDAĞLI G.
BREAST CANCER RESEARCH AND TREATMENT, cilt.145, sa.3, ss.605-614, 2014 (SCI İndekslerine Giren Dergi)
- LIII. **Spheroid formation and invasion capacity are differentially influenced by co-cultures of fibroblast and macrophage cells in breast cancer**
Rama-Esendagli D., ESENDAĞLI G., Yilmaz G., Guc D.
MOLECULAR BIOLOGY REPORTS, cilt.41, sa.5, ss.2885-2892, 2014 (SCI İndekslerine Giren Dergi)
- LIV. **Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line**
Sengel-Turk C. T. , Hascicek C., DOĞAN A., ESENDAĞLI G., GUC D., GONUL N.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.24, sa.2, ss.166-172, 2014 (SCI İndekslerine Giren Dergi)
- LV. **A co-stimulatory trap set by myeloid leukemia cells**
Esendagli G.
ONCOIMMUNOLOGY, cilt.2, sa.6, 2013 (SCI İndekslerine Giren Dergi)
- LVI. **Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands**
Dolen Y., ESENDAĞLI G.
EUROPEAN JOURNAL OF IMMUNOLOGY, cilt.43, sa.3, ss.747-757, 2013 (SCI İndekslerine Giren Dergi)
- LVII. **Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy**
ESENDAĞLI G., Kurne A. T. , Sayat G., Kilic A. K. , Guc D., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, cilt.255, ss.81-84, 2013 (SCI İndekslerine Giren Dergi)
- LVIII. **The effect of granulocyte colony stimulating factor receptor gene missense single nucleotide polymorphisms on peripheral blood stem cell enrichment**
CAMURDANOĞLU B. Z. , ESENDAĞLI G., Ozdemir E., CANPINAR H., GUC D., KANSU E.

CYTOKINE, cilt.61, sa.2, ss.572-577, 2013 (SCI İndekslerine Giren Dergi)

- LIX. **Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells**
Sengel-Turk C. T. , Hascicek C., DOĞAN A., ESENDAĞLI G., Guc D., Gonul N.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, cilt.38, sa.9, ss.1107-1116, 2012 (SCI İndekslerine Giren Dergi)
- LX. **Injectable biodegradable polymeric system for preserving the active form and delayed-release of camptothecin anticancer drugs**
Mert O., ESENDAĞLI G., DOĞAN A., DEMİR A. G.
RSC ADVANCES, cilt.2, sa.1, ss.176-185, 2012 (SCI İndekslerine Giren Dergi)
- LXI. **Expression of chemokine-like receptor 1 (CMKLR1) on J744A.1 macrophages co-cultured with fibroblast and/or tumor cells: Modeling the influence of microenvironment**
Rama D., ESENDAĞLI G., Guc D.
CELLULAR IMMUNOLOGY, cilt.271, sa.1, ss.134-140, 2011 (SCI İndekslerine Giren Dergi)
- LXII. **Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy**
Kurte A., Guc D., CANPINAR H., Aydın O. F. , Sayat G., Yorubulut M., ESENDAĞLI G., KARABUDAK R.
ACTA NEUROLOGICA SCANDINAVICA, cilt.123, sa.1, ss.8-12, 2011 (SCI İndekslerine Giren Dergi)
- LXIII. **Immune Compartmentalization of T cell Subsets in Chemically-induced Breast Cancer**
Fahmi T., ESENDAĞLI G., Yilmaz G., Kansu E., Guc D.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, cilt.72, sa.4, ss.339-348, 2010 (SCI İndekslerine Giren Dergi)
- LXIV. **CD40-1C > T single nucleotide polymorphism and CD40 expression on breast tumors**
Dolen Y., Yilmaz G., ESENDAĞLI G., Guler N. E. , Guc D.
CYTOKINE, cilt.50, sa.3, ss.243-244, 2010 (SCI İndekslerine Giren Dergi)
- LXV. **Transfection of myeloid leukaemia cell lines is distinctively regulated by fibronectin substratum**
ESENDAĞLI G., CANPINAR H., DOĞAN A., Akkaya M., Kansu E., Guc D.
CYTOTECNOLOGY, cilt.61, ss.45-53, 2009 (SCI İndekslerine Giren Dergi)
- LXVI. **Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors**
Bilensoy E., Sarisozen C., Esendagli G., Doğan A., Aktas Y., Şen M., Mungan N. A.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.371, ss.170-176, 2009 (SCI İndekslerine Giren Dergi)
- LXVII. **CONSTRUCTION OF BICISTRONIC B-GALACTOSIDASE REPORTER PLASMIDS FOR EUKARYOTIC EXPRESSION OF CD40 LIGAND (CD40L) GENE**
Dolen Y., ESENDAĞLI G., Oskay S., Guc D.
IUBMB LIFE, cilt.61, sa.3, ss.335, 2009 (SCI İndekslerine Giren Dergi)
- LXVIII. **Fibronectin promotes the phorbol 12-myristate 13-acetate-induced macrophage differentiation in myeloid leukemia cells**
ESENDAĞLI G., CANPINAR H., Yilmaz G., KAYMAZ F. F. , Kansu E., Guc D.
INTERNATIONAL JOURNAL OF HEMATOLOGY, cilt.89, sa.2, ss.167-172, 2009 (SCI İndekslerine Giren Dergi)
- LXIX. **Coexistence of different tissue tumorigenesis in an N-methyl-N-nitrosourea-induced mammary carcinoma model: a histopathological report in Sprague-Dawley rats**
ESENDAĞLI G., Yilmaz G., CANPINAR H., Gunel-Ozcan A., Guc M. O. , Guc D.
LABORATORY ANIMALS, cilt.43, sa.1, ss.60-64, 2009 (SCI İndekslerine Giren Dergi)
- LXX. **Molecular and functional analysis of a novel recombinant clone of rat (Rattus norvegicus) CD40 ligand (CD40L) gene**
ESENDAĞLI G., Gunel-Ozcan A., CANPINAR H., Guc D.
MOLECULAR BIOLOGY REPORTS, cilt.36, sa.1, ss.83-89, 2009 (SCI İndekslerine Giren Dergi)
- LXXI. **Primary tumor cells obtained from MNU-induced mammary carcinomas show immune heterogeneity which can be modulated by low-efficiency transfection of CD40L gene**
ESENDAĞLI G., CANPINAR H., Yilmaz G., Gunel-Ozcan A., Guc M. O. , Kansu E., Guc D.
CANCER BIOLOGY & THERAPY, cilt.8, sa.2, ss.136-142, 2009 (SCI İndekslerine Giren Dergi)

- LXXII. **Adhesion of beta1 integrin to fibronectin regulates CAM-DR phenotype via p21(WAF1/cip1) in HL60 acute myeloid leukemia (AML) cells**
CANPINAR H., ESENDAĞLI G., Kansu E., Ozcan A. G. , Guc D.
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.38, sa.2, ss.97-104, 2008 (SCI İndekslerine Giren Dergi)
- LXXIII. **Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer**
Esendagli G., Bruderek K., Goldmann T., Busche A., Branscheid D., Vollmer E., Brandau S.
LUNG CANCER, cilt.59, sa.1, ss.32-40, 2008 (SCI İndekslerine Giren Dergi)
- LXXIV. **Salmonella typhimurium aroB encoding murine IL 18 or CD40L evaluation for gene therapy**
AYDIN D., GÜNEL ÖZCAN A., MENAGER N., ESENDAĞLI G., GÜÇ M. O. , HAYRAN K. M. , Kansu E., GÜÇ D.
Febs Journal, cilt.273, ss.49-50, 2006 (SCI Expanded İndekslerine Giren Dergi)
- LXXV. **pTARGET vector carrying IL 18 or CD40L genes for attenuated Salmonella typhimurium mediated gene therapy**
BEK D., ESENDAĞLI G., GÜNEL ÖZCAN A., GÜÇ D., GÜÇ M. O. , Kansu E.
Blood, cilt.102, ss.491, 2003 (SCI Expanded İndekslerine Giren Dergi)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Design and synthesis of novel peptidomimetics for cancer immunotherapy**
Kose C., Uysal E., Yazici B., Tugay Z., Dingis-Birgul S. I. , Yanik H., Tavukcuoglu E., Gulyuz S., AKDEMİR A., ESENDAĞLI G., et al.
ORGANIC COMMUNICATIONS, cilt.13, sa.3, ss.89-102, 2020 (ESCI İndekslerine Giren Dergi)
- II. **Tümörlerde Doğal İmmün Yanıt**
ÖZMEN F., ESENDAĞLI G.
Türkiye Klinikleri J Med Oncol-Special Topics, cilt.10, ss.104-111, 2017 (Diğer Kurumların Hakemli Dergileri)
- III. **Atypical Chemokine Receptors in Cancer**
sarmadi p., TUNALI G., ESENDAĞLI G.
Acta Medica, 2016 (Diğer Kurumların Hakemli Dergileri)

Kitap & Kitap Bölümleri

- I. **Biomaterials Surface Properties: Implications in Immune Response**
ENDOĞAN TANIR T., ESENDAĞLI G., AKSOY E. A.
Biomaterials and Immune Response: Complications, Mechanisms and Immunomodulation, Vrana, Nihal Engin, Editör, CRC Press Taylor Francis Group, ss.121-140, 2018

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Büyük veriden hücre karakterizasyonuna: Transkripsiyon faktörü kataloglarının oluşturulması**
İMREN G., KARAOSMANOĞLU B., ÇELEBİ SALTIK B., ESENDAĞLI G., TAŞKIRAN Z. E.
Tıbbi Biyoloji ve Genetik Kongresi, Türkiye, 27 - 30 Ekim 2019
- II. **Effect of Formulation Parameters on PLGA and PLGA-PEG Nanoparticles Formulated with Double Emulsion Method**
Arslan F. B. , ÖZTÜRK K., ESENDAĞLI G., ÇALIŞ S.
8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 Ekim 2019
- III. **A Modified Cell Culture Method for Evaluation of Chitosan Nanoparticles**
ÖZTÜRK K., Arslan F. B. , Tavukcuoğlu E., ESENDAĞLI G., ÇALIŞ S.
8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 Ekim 2019

- IV. **Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin In Breast Cancer**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 Ekim 2019, cilt.1, ss.184-186
- V. **A positive feedback mechanism between basal-like breast cancer cells and monocytes through STAT3/IL-1 beta/fibronectin can support chronic inflammation in the tumor microenvironment**
Tunali G., ESENDAĞLI G.
17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, Çin, 19 - 23 Ekim 2019, cilt.49, ss.486
- VI. **STAT3-mediated atypical IFN-gamma signaling modulates the PD-1 ligands in CD11b-positive subpopulation of MDS and AML cells**
Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.
17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, Çin, 19 - 23 Ekim 2019, cilt.49, ss.90
- VII. **Circulating myelin oligodendrocyte glycoprotein (MOG)-specific B cells stratify patients with serum MOG-antibodies**
Winklmeier S., Schlueter M., Spadaro M., Thaler F. S. , Vural A., Gerhards R., Macrini C., Mader S., Kurne A., İNAN B., et al.
2nd Joint Meeting of the German-Society-for-Immunology (DGfI) and the Italian-Society-of-Immunology-Clinical-Immunology-and-Allergology (SIICA), Munich, Almanya, 10 - 13 Eylül 2019, cilt.49, ss.77
- VIII. **Transcriptomic and immunophenotypic analyses on natural killer cells in RRMS patients under fingolimod therapy**
Acar-Ozen N. P. , TUNCER A., Ozkazanc D., Ozbay F. G. , KARAOSMANOĞLU B., Goksen S., Taskiran E., ESENDAĞLI G., KARABUDAK R.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.664-665
- IX. **Small cell lung cancer stem cells show adaptive resistance through effectively inducing t cell activation and modulating the expression of co-inhibitory receptor**
KURŞUNEL M. A. , TAŞKIRAN Z. E. , ESENDAĞLI G.
International Molecular Immunology Immunogenetics Congress IV (MIMIC IV), Bursa, Türkiye, 27 - 29 Nisan 2019, ss.29
- X. **Transcript variants of MDSC-related surface markers in breast cancer and colorectal cancer**
horzum u., Yoyen-Ermis D., Yılmaz B. K. , KARAKOÇ D., ESENDAĞLI G.
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 Kasım 2018
- XI. **Analysis of spleen-derived MDSCs in pancreatic and gastric cancer patients**
tavukcuoglu e., horzum u., Yoyen-Ermis D., aydin b., Yılmaz B. K. , ÜNER A., KARAKOÇ D., Hamaloglu E., ESENDAĞLI G.
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 Kasım 2018
- XII. **Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis**
Yoyen-Ermis D., Sevmis M., Aydin C., Bilgic E., KORKUSUZ P., ÜNER A., Hamaloglu E., KARAKOÇ D., ESENDAĞLI G.
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 Kasım 2018
- XIII. **In Vitro Evaluation of Co-Loaded Drug Delivery, Theranostic Liposomes in Human Non-Small Cell Lung Cancer**
KARPUZ M., KURŞUNEL M. A. , SİLİNDİR GÜNAY M., DOĞAN A., ESENDAĞLI G., ÖZER A. Y.
19th International Pharmaceutical Technology Symposium, Antalya, Türkiye, 17 Eylül 2018, ss.182-183
- XIV. **APOPTOTIC GENE THERAPY BY NOVEL DEVELOPED PARTIALLY HYDROLYSED PEtOx BASED MICELLAR NANOCARRIERS ON MCF-7 BREAST CANCER CELLS**
KARA A., ÖZTÜRK N., ESENDAĞLI G., ÖZKÖSE U. U. , Gulyuz S., bolat z. b. , Yılmaz O., TELCİ D., BOZKIR A., VURAL İ.
IPTS2018, 17 - 19 Eylül 2018
- XV. **PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED**

MESOPOROUS SILICA NANOPARTICLES

TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu e., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
19th International Pharmaceutical Technology Symposium-IPTS 2018, 17 - 19 Eylül 2018

- XVI. **Characterization of Circulating Exosomes and Analysis of Exosomal microRNAs**
zeynep t., AKKAYA ULUM Z. Y., YERSAL N., AKBABA T. H., Horzum U., ESENDAĞLI G., KORKUSUZ P., peynircioglu b.
6th International Congress of the Molecular Biology of Association of Turkey, 5 - 08 Eylül 2018
- XVII. **Preparation and Comparative Evaluation of Gemcitabine Loaded Polymeric Nanoparticles for Pancreatic Cancer Treatment**
Arslan F. B., ÖZTÜRK K., ESENDAĞLI G., ÇALIŞ S.
45th Annual Meeting Exposition of the Controlled Release Society, 22 - 24 Temmuz 2018
- XVIII. **The Fibrogenic Activation Kinetics of Stromal Stem Cells in Three Different Skeletal Muscle Degeneration Models**
ÖZDEMİR SAKA C., AKÇAY D., YÖYEN ERMİŞ D., ESENDAĞLI G., KOCAEFE Y. Ç.
43rd FEBS CONGRESS, 7 - 12 Temmuz 2018
- XIX. **Comparative Transcriptome Analysis of Distinct Stromal Cell Populations During Extracellular Matrix Remodeling in Skeletal Muscle**
ÖZDEMİR SAKA C., AKÇAY D., YÖYEN ERMİŞ D., TAŞKIRAN Z. E., ESENDAĞLI G., KOCAEFE Y. Ç.
13th Meeting of the Mediterranean Society of Myology, 27 - 29 Haziran 2018, cilt.37, ss.129-183
- XX. **Leptinin Spermatogonyal Kok Hücreler Üzerindeki Etkisi**
YERSAL N., KÖSE S., Utku H., ESENDAĞLI G., Sinan O., KORKUSUZ P.
XIV. Ulusal Histoloji ve Embriyoloji Kongresi, Türkiye, 10 Mayıs 2019 - 13 Mayıs 2018
- XXI. **Gemcitabine delivery via dendrimer carriers decorated with anti-VGFR1 antibody to target tumor-induced myeloid cells**
KURŞUNEL M. A., Yoyen Ermis D., OZTURK ATAR K., AYDIN Ç., OZKAZANC D., GURBUZ M. U., ÜNER A., TULU M., ÇALIŞ S., ESENDAĞLI G.
Myeloid Derived Suppressor Cells: Identification and implications in Human Diseases, 16 - 18 Nisan 2018
- XXII. **Passive Targeting of Gemcitabine Using Poly(Caprolactone) Nanoparticles for Cancer Treatment**
ÖZTÜRK K., Arslan F. B., ESENDAĞLI G., ÇALIŞ S.
2nd Gazi Pharma Symposium Series, 11 - 13 Ekim 2017
- XXIII. **Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers**
ÖZTÜRK K., ESENDAĞLI G., Gürbüz M. U., TULU M., ÇALIŞ S.
Advanced School in Nanomedicine, 25 - 28 Eylül 2017
- XXIV. **Dual effects of chlorophylline on breast cancer cell proliferation in vivo and in vitro**
ÖZCAN M., Musad Y., ESENDAĞLI G., CANPINAR H., AKSOY Y.
42nd Congress of the Federation-of-European-Biochemical-Societies (FEBS) on From Molecules to Cells and Back, Jerusalem, İsrail, 10 - 14 Eylül 2017, cilt.284, ss.259
- XXV. **Novel Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles For Paclitaxel Delivery in Recurrent Metastatic Breast Cancer**
ERDOĞAR N., ESENDAĞLI G., NIELSEN T. T., ESENDAĞLI YILMAZ G., SARGON M. F., ÖNER L., BİLENSOY E.
Innovation in Medicine Summit-3, 11 - 13 Mayıs 2017
- XXVI. **NOVEL POLYMERIC MICELLES BASED ON Poly-(2-Ethyl-2-Oxazoline)-co-Poly(ethylenimine)-block-Poly(ε-caprolactone) PETox-co-PEI-b-PCL BLOCK COPOLYMER WITH VARIOUS HYDROLYSIS DEGREE TO EVALUATE THE EFFECT OF TRANSFECTION EFFICIENCY ON MCF-7 CELLS**
KARA A., ÖZTÜRK N., ESENDAĞLI G., BOLAT z. b., GÜLYÜZ s., TELCİ D., YILMAZ ö., BOZKIR A., VURAL İ.
AAPS 2017 NATIONAL BIOTECHNOLOGY CONGRESS, San Diego, Amerika Birleşik Devletleri, 01 Mayıs 2107 - 03 Mayıs 2017
- XXVII. **Increased monocytic myeloid-derived suppressor cells in small-cell lung cancer implicate interaction between small cell lung cancer cells and monocytes**
KURŞUNEL M. A., Yoyen Ermis D., Horzum U., Esendagli D., ESENDAĞLI G.
Analysis and Clinical Monitoring of Myeloid Regulatory Cells, Brno, Çek Cumhuriyeti, 1 - 03 Mart 2017

- XXVIII. **Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles Lessons and Challenges**
ŞAHİN A., Yerlikaya F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
GPEN 2016, 9 - 12 Kasım 2016
- XXIX. **Intracellular delivery and intraperitoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method**
ŞAHİN A., ESENDAĞLI G., Fırat Y., Serhat K., Yöyen Ermis D., Horzum U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 - 21 Eylül 2016
- XXX. **The effect of fingolimod treatment on natural killer cells**
Acar N. P., KARABUDAK R., Ozkazanc D., Sayat-Gurel G., ESENDAĞLI G., TUNCER A.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.176-177
- XXXI. **Effect of chlorophylline as an antioxidant molecule on glutathione and related enzymes in breast cancer model**
ÖZCAN M., Beyramzadeh M., ESENDAĞLI G., AKSOY Y.
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Türkiye, 3 - 08 Eylül 2016, cilt.283, ss.408
- XXXII. **Active targeting of anti VEGFR 1 monoclonal antibody conjugated gemcitabine loaded dendrimers to pancreatic cancer and in vitro in vivo evaluation**
ÖZTÜRK K., gurbuz u. m., TÜLÜ M., ESENDAĞLI G., ÇALIŞ S.
18th International Pharmaceutical Technology Symposium, 18 - 21 Eylül 2016
- XXXIII. **Costimulatory signals derived from myeloid leukemia cells contribute to functional exhaustion in CD4(+) T cells**
Ozkazanc D., BÜYÜKAŞIK Y., ESENDAĞLI G.
International Congress of Immunology (ICI), Melbourne, Avustralya, 21 - 26 Ağustos 2016, cilt.46, ss.1092-1093
- XXXIV. **Targeting myeloid derived suppressor cells MDSCs in pancreatic cancer by gemcitabine loaded anti VEGFR1 antibody coated dendrimers carriers**
ÖZTÜRK K., yöyen ermiş d., özkazanç d., gürbüz m. u., TÜLÜ M., ÇALIŞ S., ESENDAĞLI G.
3rd International Molecular Immunology & Immunogenetics Congress MIMIC-III, 27 - 30 Nisan 2016
- XXXV. **B7-H3 molekülünün küçük-hücreli akciğer kanseri için immünolojik biyobelirteç olarak değerlendirilmesi**
KURŞUNEL M. A., ESENDAĞLI D., ESENDAĞLI G.
22. Ulusal Kanser Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017
- XXXVI. **THE PROTECTIVE ROLE OF CHLOROPHYLLINE Cu COMPLEX ON N METHYL N NITROSOUREA INDUCED BREAST CANCER MODEL**
ÖZCAN M., BÜBER E., CEYHAN D., beyramzadeh m., BACANLI M., ESENDAĞLI G., AKSOY Y.
XXVII. ULUSAL BİYOKİMYA KONGRESİ, 3 - 06 Kasım 2015, cilt.40
- XXXVII. **Evaluation of Dendrimer Based Nanocarrier System for Pancreatic Cancer Therapy**
ÖZTÜRK K., Gürbüz M. U., ESENDAĞLI G., TÜLÜ M., ÇALIŞ S.
2015 AAPS Annual Meeting, 25 - 29 Ekim 2015
- XXXVIII. **Evaluation of Developed Dendrimer based Nanocarrier System for Pancreatic Cancer Therapy**
ÖZTÜRK K., Gürbüz M., Tülü M., ESENDAĞLI G., ÇALIŞ S.
2015 AAPS Annual Meeting and Exposition, 25 Ekim - 29 Haziran 2015
- XXXIX. **Immune modulatory effects of the small peptide molecules derived from CXCL chemokines**
Yöyen Ermiş D., Karaşar P., ESENDAĞLI G.
World Immunoregulation meeting - IX, 18 - 21 Mart 2015
- XL. **In Vitro and In Vivo Evaluation of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin Derivatives**
ERDOĞAR N., TERNDRUP N., ÖNER L., ESENDAĞLI G., BİLENSOY E.
4th European Conference on Cyclodextrins (EUROCD 2015), 6 - 09 Ekim 2015
- XLI. **Mesenchymal stem cells induce proliferation of NCI-H82 small cell lung cancer**
KOPRU C. Z., CAGNAN I., Akar-Soycan I., ESENDAĞLI G., KORKUSUZ P., ÖZCAN A.

Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finlandiya, 17 - 20 Eylül 2015, cilt.26

- XLII. **pCR3::GITRL transfected MSCs induce apoptotic cell death and SIVA1 expression in SCLC-21H lung cancer cell line**
KOPRU C. Z. , KORKUSUZ P., CAGNAN I., Akar-Soycan I., ESENDAĞLI G., ÖZCAN A.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finlandiya, 17 - 20 Eylül 2015, cilt.26
- XLIII. **Selective expression of CCRL2 transcript variants associates with inflammatory response in breast cancer**
Sarmadi P., TUNALI G., YILMAZ G., Yılmaz K., ESENDAĞLI G.
4th European Congress of Immunology, 6 - 09 Eylül 2015
- XLIV. **Fibronectin production in basal like breast cancer cells is regulated by pro inflammatory cytokines and may influence myeloid cell maturation**
TUNALI G., ESENDAĞLI G.
4th European Congress of Immunology, 6 - 09 Eylül 2015
- XLV. **The effect of co stimulatory signals derived from acute myeloid leukemia cells AML on helper T lymphocyte activation and exhaustion**
OZKAZANC D., ESENDAĞLI G.
4th European Congress of Immunology, 6 - 09 Eylül 2015
- XLVI. **Nanopartiküller ile işaretli pGITRL aktarılmış mezenkimal kök hücrelerin küçük hücreli akciğer kanseri hücreleriyle görüntülenmesi**
KÖPRÜ C. Z. , GÜNEL ÖZCAN A., Cagnan I., AKAR SOYCAN İ., ESENDAĞLI G., KORKUSUZ P.
22.nci Elektron Mikroskopi Kongresi (EMK 2015), İstanbul, Türkiye, 2 - 04 Eylül 2015
- XLVII. **Can acute myeloid leukemia cells act as myeloid derived suppressor cells for immune escape**
YÖYEN ERMİŞ D., TUNALI G., KARAŞAR P., ESENDAĞLI G.
Young Investigator Workshop Immunosystem and Microenvironments Implications for Cancer Therapy, 24 - 26 Ağustos 2015
- XLVIII. **The protective role of chlorophylline-Cu complex on N-methyl-N-nitrosourea induced breast cancer model in Sprague Dawley Rats: glutathione and DNA damage levels**
ÖZCAN M., BÜBER E., Ceyhan D., BACANLI M., Beyramzadeh M., ESENDAĞLI G., AKSOY Y.
40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Almanya, 4 - 09 Temmuz 2015, cilt.282, ss.265
- XLIX. **Optimization by 32 Factorial Design of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin**
ERDOĞAR N., ÖNER L., ESENDAĞLI G., NIELSEN T., BİLENSOY E.
EUFEPS Annual Meeting, 15 - 17 Haziran 2015
- L. **Evaluation of Th17 cell infiltration in thymectomy materials of acetylcholine receptor antibody positive myasthenia gravis patients**
Bekircan Kurt E., Mehdikanova L., Öner S., ESENDAĞLI G., KARABULUT E., Kurne A.
AAN 67th Annual Meeting, 6 - 10 Nisan 2015
- LI. **Formyl-methionyl-leucyl-phenylalanine (fMLP) peptide as an adjuvant in experimental autoimmune encephalomyelitis (EAE): modulation of neutrophil granulocytes**
KILIÇ A., Tuncer-Kurne A., ESENDAĞLI G., Sayat G., TALİM B., KARABUDAK R.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.136
- LII. **Evaluation of Th17-related parameters in multiple sclerosis patients under immunomodulatory IFN-beta 1 therapy**
Sayat G., Kurne A., ESENDAĞLI G., Guc D., KARABUDAK R.
11th International Congress of Neuroimmunology (ISNI), Massachusetts, Amerika Birleşik Devletleri, 4 - 08 Kasım 2012, cilt.253, ss.77-78
- LIII. **Functional analysis of neutrophils cultured in supernatant of CXCL7 overexpressing lung cancer**

cells

ÜNVER N., ESENDAĞLI G., GUC D.

European Congress of Immunology, Glasgow, İngiltere, 5 - 08 Eylül 2012, cilt.137, ss.608

LIV. Cloning of atypical chemokine receptors CRAM-A and CRAM-B for comparative functional analysis

Sarmadi P., ESENDAĞLI G.

European Congress of Immunology, Glasgow, İngiltere, 5 - 08 Eylül 2012, cilt.137, ss.188

LV. Dynamic induction of immune escape by activated T cells via regulation of B7-ligands on myeloid leukemia cells

ESENDAĞLI G., Dolen Y.

European Congress of Immunology, Glasgow, İngiltere, 5 - 08 Eylül 2012, cilt.137, ss.206-207

LVI. Differences of myeloid cell subsets in a chemically induced rat breast carcinoma model

DOLEN Y., GÜNAYDIN G., ESENDAĞLI G., GUC D.

European Congress of Immunology, Glasgow, İngiltere, 5 - 08 Eylül 2012, cilt.137, ss.606

LVII. Salmonella typhimurium aroB-encoding murine IL-18 or CD40L: evaluation for gene therapy

Aydin D., Gunel-Ozcan A., Menager N., Esendagli G., Guc M. O. , Hayran M., Kansu E., Guc D.

31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Türkiye, 24 - 29 Haziran 2006, cilt.273, ss.49-50

LVIII. pTARGET vector carrying IL-18 or CD40L genes for attenuated Salmonella typhimurium mediated gene therapy.

Bek D., Esendagli G., Gunel-Ozcan A., Guc D., Guc M., Kansu E.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102

Desteklenen Projeler

ESENDAĞLI G., TÜBİTAK Projesi, Prostat ve meme kanseri teşhis ve tedavisinde kullanılacak Poli 2 Etil 2 Oksazolin Petox esaslı çok işlevsel taşıyıcı sistemlerin geliştirilmesi, 2014 - Devam Ediyor

BİLENSOY E., Varan G., ESENDAĞLI G., Varan C., Yükseköğretim Kurumları Destekli Proje, Paklitaksel yüklü siklodekstrin nanopartiküllerin antitümöral etkinliğinin araştırılması, 2017 - 2020

ESENDAĞLI G., ÖZBAY F., Yükseköğretim Kurumları Destekli Proje, T lenfosit yanıtlarının nötrofil, monosit ve akciğer kanseri hücrelerini içeren kokültürlerde analizi, 2018 - 2019

ESENDAĞLI G., TUNALI G., Yükseköğretim Kurumları Destekli Proje, Meme kanseri hücreleri tarafından üretilen fibronektinin miyeloid hücre karakteri üzerine etkisi, 2018 - 2019

KARAKOÇ D., YORGUN H., ÜNAL CANGÜL Ş., ER ÖZTAŞ Y., ESENDAĞLI G., KONAŞ E., ÇALIK BAŞARAN N., KILIÇASLAN B., EKİNCİ S., HELVACI E., et al., Yükseköğretim Kurumları Destekli Proje, Hacettepe Üniversitesi Tıp Fakültesi Dergisi Acta Medica'nın Yapılandırılması, 2017 - 2019

ÖZER A. Y. , SİLİNDİR GÜNAY M., ESENDAĞLI G., KARPUZ M., Yükseköğretim Kurumları Destekli Proje, Küçük Hücreli Dışı Akciğer Kanseri Aktif Hedeflendirilmiş Nanoboyutlu Teranostik Kombine İlaç Taşıyan Sistemlerin Formülasyonu ve Etkinliğinin Saptanması, 2017 - 2019

TUNCER M. A. , ACAR N. P. , ESENDAĞLI G., SAYAT-GÜREL G., KARABUDAK R., Yükseköğretim Kurumları Destekli Proje, Multiple Skleroz Hastalarında CCRL2 Atipik Kemokin Reseptör Polimorfizminin Kemokin Düzeyleri ve Hastalık Süreci ile İlişkisi, 2015 - 2019

KORKUSUZ P., ÖZKAVUKCU İ. S. , YERSAL N., ESENDAĞLI G., KÖSE S., Yükseköğretim Kurumları Destekli Proje, Leptinin spermatogonyal kök hücre kriyoprezervasyonundaki etkisinin araştırılması, 2017 - 2018

KARAKOÇ D., DİNÇER H. A. , Ermiş D. Y. , ESENDAĞLI G., Horzum U., Yükseköğretim Kurumları Destekli Proje, Meme kanserinin karaciğer metastazında karaciğer rezeksiyonunun immünolojik etkileri, 2017 - 2018

KARABULUT İ., DİNÇSOY A. B. , TUNCER M., CANSARAN DUMAN D., ESENDAĞLI G., YÖYEN ERMİŞ D., ZEYBEK N. D. , Yükseköğretim Kurumları Destekli Proje, 4T1 Hücreleriyle Farelerde Oluşturulan Meme Karsinomu Üzerine Usnik Asit Sekonder Metabolitinin in vivo Etkileri, 2017 - 2018

ESENDAĞLI G., Tavukçuoğlu E., Yükseköğretim Kurumları Destekli Proje, PDL2 kostimülatör molekülünü ifade eden akut miyeloid lösemi hücrelerinin yardımcı T hücre aktivasyonuna etkisi, 2017 - 2018

GÜRSOY R. N. , TİMUR S. S. , ESENDAĞLI G., Yükseköğretim Kurumları Destekli Proje, Meme Kanseri Tedavisinde Aktif Hedeflendirme Amacıyla Kullanılmak Üzere Nano Boyutlu İlaç Taşıyıcı Sistemlerin Nanofarmasötikler Tasarımı ve in vitro Değerlendirilmesi, 2017 - 2018

ESENDAĞLI G., KURŞUNEL M. A. , Yükseköğretim Kurumları Destekli Proje, MD ANDERSON Kanseri Enstitüsü tarafından düzenlenen Global Academic Program 2017 Kongresine Katılım, 2017 - 2017

ESENDAĞLI G., ÜNER A., KURŞUNEL M. A. , Yükseköğretim Kurumları Destekli Proje, B lenfoma hücrelerinde B7 ailesi kostimülör moleküllerin araştırılması ve T hücre aktivasyonuna ve yorulmasına etkileri, 2016 - 2017

ESENDAĞLI G., Yükseköğretim Kurumları Destekli Proje, CXCL KEMOKİNLERDEN TÜREVLİENEN İMMÜNMODÜLATÖR PEPTİTLER, 2016 - 2017

ESENDAĞLI G., Yükseköğretim Kurumları Destekli Proje, Miyeloid lösemi hücrelerinden kaynaklanan kostimülör sinyaller CD4 T hücrelerde fonksiyonel tükenmeye neden olur, 2016 - 2016

ESENDAĞLI G., Karaşar P., Yükseköğretim Kurumları Destekli Proje, Yardımcı T hücre yanıtları bazalbenzeri meme kanseri hücreleri tarafından devam ettirilir ve PD1 ligandlarının artışı ile immün düzenlenmesini sağlar, 2015 - 2016

ESENDAĞLI G., Özkazanç D., Yükseköğretim Kurumları Destekli Proje, Uyarılabilen kostimülör ligand (ICOS-LG) eksprese eden akut miyeloid lösemi (AML) hücrelerinin T lenfosit aktivasyonuna ve yorulmasına etkisi, 2015 - 2016

ESENDAĞLI G., Yükseköğretim Kurumları Destekli Proje, İmmünoterapi Amaçlı Deneysel Onkoloji Sistemlerinin Geliştirilmesi, 2014 - 2016

ESENDAĞLI G., TÜBİTAK Projesi, CXCL kemokin öncül dizilerinden türetilen küçük peptid moleküllerinin immün düzenleyici etkisinin değerlendirilmesi, 2013 - 2016

ESENDAĞLI G., Yükseköğretim Kurumları Destekli Proje, All-trans retinoik asit (ATRA) ve 1,25-dihidroksivitamin D3 (vitamin D3) ile uyarılan akut miyeloid lösemi hücrelerinin T hücre yanıtları üzerine etkisi, 2014 - 2015

Atıflar

Toplam Atıf Sayısı (WOS):618

h-indeksi (WOS):14